Search Results

You are looking at 1 - 10 of 122 items for :

  • "febrile neutropenia" x
Clear All
Full access

Gary H. Lyman and Marek S. Poniewierski

need to consider a range of risk factors for the occurrence and consequences of febrile neutropenia (FN), defined as body temperature >38.5°C or 2 consecutive measurements >38°C with an absolute neutrophil count <0.5 × 10 9 /L. Risk Factors for FN

Full access

Abiy Agiro, Andrea DeVries, Jennifer Malin and Michael J. Fisch

Factors recommend febrile neutropenia (FN) prophylaxis using a colony-stimulating factor (CSF) when risk, based on the chemotherapy regimen and patient risk factors, is “high” (>20%). 7 CSF prophylaxis may also be considered based on patient risk factors

Full access

Betsy L. Althaus

-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumors . Eur J Cancer 2006 ; 42 : 2433 – 2453 . 8. Scott SD Chrischilles EA Link BK . Days of prophylactic

Full access

Anna M. Gibson and Claire Sutherby

Introduction: Chemotherapy-induced febrile neutropenia is a medical emergency. Delays in time to appropriate broad spectrum antibiotic therapy significantly increase morbidity and mortality. The purpose of this project is to improve outcomes in

Full access

David da Silva Dias, Catarina Jorge, Mafalda Baptista, Ana Júlia Arede, Paulo Luz, Tânia Madureira and Beatriz Gosalbez

Introduction: Febrile neutropenia (FN) induced by chemotherapy (ChT) arises until 6 weeks after the last cycle, usually between 5 and 10 days post-ChT. Infection risk is 20%–30%. It is difficult to stratify patients with low risk of complications

Full access

Demetrios N. Kyriacou, Borko Jovanovic and Olga Frankfurt

several studies that illustrate the delayed times to initial antibiotic treatment for adults with FN in EDs Table 1 Current Guidelines for Timing of Initial Antibiotic Treatment of Adult Patients With Febrile Neutropenia worldwide, indicating

Full access

Deborah S. Yolin-Raley, Ibiayi Dagogo-Jack, Heidi B. Niell, Robert J. Soiffer, Joseph H. Antin, Edwin P. Alyea III and Brett E. Glotzbecker

febrile neutropenia workup. As of July 2012, CXRs were ordered according to physician preference, instead of according to strict adherence to guidelines. Most of the CXRs ordered for the inpatients were obtained within 24 hours of initiation of antibiotics

Full access

Yanli Li, Leila Family, Su-Jau Yang, Zandra Klippel, John H. Page and Chun Chao

Background Febrile neutropenia (FN) is a serious adverse effect of myelosuppressive chemotherapy that can affect treatment by contributing to dose delays and reductions. 1 FN often requires hospitalization and incurs a significant healthcare

Full access

Leila Family, Yanli Li, Lie Hong Chen, John H. Page, Zandra K. Klippel and Chun Chao

Risk of developing chemotherapy-induced febrile neutropenia (FN) depends on patient-, treatment-, and disease-related characteristics. 1 In our prior investigation, several chronic comorbidities were associated with significantly increased FN

Full access

Derek Weycker, Xiaoyan Li, Rich Barron, Hongsheng Wu, P.K. Morrow, Hairong Xu, Maureen Reiner, Jacob Garcia, Shivani K. Mhatre and Gary H. Lyman

Background Neutropenia is a common side effect of myelosuppressive chemotherapy that increases the risk of infection, which is typically signaled by fever. When neutropenic patients develop fever (ie, febrile neutropenia [FN]), the likelihood